Efficacy and Safety of Intra-Articular Platelet-Rich Plasma in Osteoarthritis Knee: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the included studies.

Study	No. trial/control (intervention)	Age (yr.) mean (trial/control)	VAS score at baseline (trial/control)	WOMAC score at baseline (trial/control)	IKDC at baseline (trial/control)
Cerza 2012 [13]	60/60 (PRP 4 IA/HA 4 IA)	66.5/66.2
Filardo 2012 [14]	54/55 (PRP 3 IA/HA 3 IA)	55/58
Patel 2013 [9]	54/50/46 (PRP 1 IA/PRP 3 IA/saline 1 IA)	53.11/51.64/53.65
Raeissadat 2015 [15]	87/73 (PRP 2 IA/HA 3 IA)	56.85/61.13		39.5 ± 17.06/28.69 ± 16.69
Filardo 2015 [6]	94/89 (PRP 3 IA/HA 3 IA)	53.32/57.55
Kavadar 2015 [4]	33/32/33 (PRP 3 IA/PRP 2 IA/PRP 1 IA)	55.2/54.9/53.6
Cole 2016 [16]	49/50 (PRP 3 IA/HA 3 IA)	55.9/56.8
Simental 2016 [27]	33/32 (PRP 3 IA/acetaminophen 500 mg tid po 6 weeks)	57.2/55.6
Forogh 2016 [16]	24/24 (PRP 1 IA/corticosteroid 1 IA)	59.13/61.13	(100 mm VAS)
Jubert 2017 [10]	35/30 (PRP 1 IA/corticosteroid 1IA)	65.56/68	(100 mm VAS)
Görmeli 2017 [17]	39/44/39/40 (PRP 3 IA/PRP 1 IA+saline 2 IA/HA 3 IA/saline 3 IA)	53.7/53.8/53.5/53.5
Su 2018 [21]	27/25/30 (PRP 2IA+IO/PRP 2 IA/HA 5 IA)	50.67/53.13
Ahmad 2018 [11]	45/44 (PRP 3 IA/HA 3 IA)	56.2/56.8
Uslu 2018 [22]	14/19/17 (PRP 3/PRP 1/corticosteroid 1)	60.4/62.3/62.8
Lisi 2018 [19]	31/31 (PRP 3 IA/HA 3 IA)	53.5/57.1
Buendía 2018 [23]	33/32/33 (PRP 1 IA/HA 1 IA/Etoricoxib 60 mg qd po 52 weeks)	56.15/56.63/57.42
Wu 2018 [20]	20/20 (PRP 1IA/saline 1 IA)	63.25/63.25
Louis 2018 [24]	24/24 (PRP 1 IA/HA 1 IA)	53.2/48.5
Lin 2019 [3]	31/29/27 (PRP 3 IA/HA 3 IA/saline 3 IA)	61.17/62.23
Di Martino 2019 [25]	85/82 (PRP 3 IA/HA 3 IA)	52.7/57.5
Elik 2019 [26]	30/27 (PRP 3 IA/saline 1 IA)	61.3/60.19
Simental 2019 [27]	17/18 (PRP 3IA/PRP 1 IA)	60.1/54.6
Huang 2019 [28]	40/40/40 (PRP 3 IA/HA 3 IA/corticosteroid 1 IA)	54.5/54.8/54.3